Short Interest in UCB SA (OTCMKTS:UCBJF) Expands By 25.7%

UCB SA (OTCMKTS:UCBJF) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 396,800 shares, a growth of 25.7% from the January 15th total of 315,600 shares. Based on an average daily volume of 100 shares, the days-to-cover ratio is currently 3,968.0 days.

UCB Stock Down 0.5 %

UCBJF opened at $190.00 on Friday. The stock’s fifty day moving average is $191.33 and its two-hundred day moving average is $181.53. UCB has a 52 week low of $110.35 and a 52 week high of $200.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.